SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System


SYNERGY - High-bleeding risk patients and DAPT: implementing the latest clinical evidence into real-world practice

Session objectives:

  • Evidence for DAPT duration in the context of coronary interventions
  • Discuss the potential benefits of bioabsorbable polymer DES in high-bleeding risk patients
  • Review of Synergy design and comleted and ongoing DAPT studies
  • To understand how to relate trial data into real world practice

Part 1

Balancing Ischemic Event Risk vs Bleeding Risk & Symposium Introduction.

Prof. Stefan James

Part 1 - Balancing Ischemic Event Risk vs Bleeding Risk & Symposium Introduction.

Part 1 - Balancing Ischemic Event Risk vs Bleeding Risk & Symposium Introduction.

Part 1

Balancing Ischemic Event Risk vs Bleeding Risk & Symposium Introduction

Prof. Stefan James

Episode 2: Review of ESC DAPT Clinical Update 2017 and Latest Evidence.

Part 2

Review of ESC DAPT Clinical Update 2017 and Latest Evidence.

Dr. Jose M de la Torre Hernandez

Part 3 - The SENIOR Trial: Decision making in ageing populations.

Part 3

The SENIOR Trial: Decision making in ageing populations.

Dr. Olivier Varenne

Part 4 - The POEM Registry: One-month DAPT in High Bleed Risk patients.

Part 4

The POEM Registry: One-month DAPT in High Bleed Risk patients.

Prof. Giulio Stefanini

Part 5 - Translating the evidence in daily clinical practice: real-world case examples.

Part 5

Translating the evidence in daily clinical practice: real-world case examples.

Dr. Andrės Iñiguez Romo

Part 6 - Session evaluation and key learnings.

Part 6

Session evaluation and key learnings.

Prof. Franz-Josef Neumann

Top